Global Single Use Bioprocesing Market Set To Grow To $3.8 Bn By 2022

06 August 2018
Pharma

Visiongain’ has launched a new pharma report Global Single Use Bioprocessing Market to 2027: Bioreactors, Tangential Flow Devices, Depth Fillers, Disposable Filter Cartridges, Media bags Containers, Mixing Systems, Tubing Assemblies, Sampling Systems, Monoclonal Antibody Production, Vaccine Production

The Single Use Bioprocessing Market is set to experience strong growth over the forecast period. The primary factor boosting the demand of Single use bioprocessing technologies includes increase in adoption and commercial acceptance of single use technologies in commercial (GMP) product manufacture and growing demand for biopharmaceuticals.

By product, media bags & containers dominates the single use bioprocessing market. It occupies a share of around 23.5% share in the total global single use bioprocessing market. This is due to media bags & containers being available from various vendors and offer quality performance required for biopharmaceuticals manufacturing. Numerous technological advancements in bioreactor designs, stirring mechanisms, and sensor systems have led to rising rate of adoption of disposable reactors from the laboratory to production scale laboratories.

The lead analyst of the report commented “Asia-Pacific and Rest of the World (RoW) are the emerging single use bioprocessing markets. These regions hold tremendous potential to become the single use bioprocessing market giants in the future. Asia-Pacific countries are estimated to demonstrate tremendous growth for bioreactors owing to the massive expansion of the biopharmaceutical sector in this region.

The rising interest of pharmaceutical organizations to enter the biopharmaceutical market will result in consolidation in the form of strategic alliances between contract manufacturing organizations (CMO’s) and large pharmaceutical/biotechnology organizations. This will result in increased investments and access to cutting-edge manufacturing technologies for CMOs”

Leading companies featured in the report include Sartorius AG, Thermo Fisher Scientific, Inc., Merck KGaA, GE Healthcare, Danaher Corporation, Eppendorf AG, Applikon Biotechnology Inc., Solaris Biotech, Bioengineering AG, BBI- Biotech GmbH

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever